Theravance Bio (TBPH) Down 6.1% Since Last Earnings Report: Can It Rebound?
https://www.zacks.com/stock/news/2287393/theravance-bio-tbph-down-6-1-since-last-earnings-report-can-it-rebound?cid=CS-ZC-FT-realtime_blog-2287393
Jun 12, 2024 - Theravance Bio (TBPH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
0
Goldman cuts 2seventy bio to neutral, cites competition concerns
https://seekingalpha.com/news/4113699-goldman-cuts-2seventy-bio-to-neutral-cites-competition-concerns?source=feed_sector_healthcare
Jun 06, 2024 - Goldman Sachs has downgraded 2seventy bio (TSVT) to neutral, citing competition concerns. Read more here.
0
Has Entera Bio (ENTX) Outpaced Other Medical Stocks This Year?
https://www.zacks.com/stock/news/2282661/has-entera-bio-entx-outpaced-other-medical-stocks-this-year?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_1-2282661
Jun 03, 2024 - Here is how Entera Bio Ltd. (ENTX) and PetIQ (PETQ) have performed compared to their sector so far this year.
0
Wall Street Analysts Predict a 235.2% Upside in Zura Bio Limited (ZURA): Here's What You Should Know
https://www.zacks.com/stock/news/2282046/wall-street-analysts-predict-a-235-2-upside-in-zura-bio-limited-zura-here-s-what-you-should-know?cid=CS-ZC-FT-tale_of_the_tape|consensus_price_target-2282046
May 31, 2024 - The consensus price target hints at a 235.2% upside potential for Zura Bio Limited (ZURA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
0
Wall Street Analysts Think Annovis Bio (ANVS) Could Surge 359.53%: Read This Before Placing a Bet
https://www.zacks.com/stock/news/2280057/wall-street-analysts-think-annovis-bio-anvs-could-surge-359-53-read-this-before-placing-a-bet?cid=CS-ZC-FT-tale_of_the_tape|consensus_price_target-2280057
May 28, 2024 - The mean of analysts' price targets for Annovis Bio (ANVS) points to a 359.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
0
Cogent Bio spikes after updating late-stage data for lead asset
https://seekingalpha.com/news/4110329-cogent-bio-stock-gains-after-cancer-trial-data?source=feed_sector_healthcare
May 24, 2024 - Cogent Biosciences (COGT) stock rose after positive Phase 3 trial data for its cancer drug combo, bezuclastinib and sunitinib, in GIST patients. Read more here.
0
Biogen (BIIB) to Buy HI-Bio to Expand Rare Disease Pipeline
https://www.zacks.com/stock/news/2277986/biogen-biib-to-buy-hi-bio-to-expand-rare-disease-pipeline?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2277986
May 23, 2024 - Biogen's (BIIB) acquisition of private biotech, HI-Bio, is set to expand its rare disease pipeline by adding the latter's lead asset, felzartamab.
0
All You Need to Know About Passage Bio (PASG) Rating Upgrade to Buy
https://www.zacks.com/stock/news/2274992/all-you-need-to-know-about-passage-bio-pasg-rating-upgrade-to-buy?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_12_zacks_rank_upgrade-2274992
May 16, 2024 - Passage Bio (PASG) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
0
Are Medical Stocks Lagging Entera Bio (ENTX) This Year?
https://www.zacks.com/stock/news/2274731/are-medical-stocks-lagging-entera-bio-entx-this-year?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_1-2274731
May 16, 2024 - Here is how Entera Bio Ltd. (ENTX) and Assembly Biosciences (ASMB) have performed compared to their sector so far this year.
0
Down -5.63% in 4 Weeks, Here's Why Kronos Bio (KRON) Looks Ripe for a Turnaround
https://www.zacks.com/stock/news/2274675/down-5-63-in-4-weeks-here-s-why-kronos-bio-kron-looks-ripe-for-a-turnaround?cid=CS-ZC-FT-tale_of_the_tape|rsi-2274675
May 16, 2024 - Kronos Bio (KRON) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
0